Hepatocellular Carcinoma
Conditions
Keywords
hepatocellular carcinoma, transcatheter arterial chemoembolization, prospective control study, best support care, survival
Brief summary
Transcatheter arterial chemoembolization (TACE) had been proved to improve the survivals for middle stage hepatocellular carcinoma (HCC), but for advanced stage HCC its' efficacy had not been proved. The investigators hypothesize that TACE also improve the survivals for advanced stage HCC. Thus, the investigators carried out this prospective control study to find out if the survivals for patients after TACE better than only best support or not.
Interventions
PROCEDUREtranscatheter arterial chemoembolization
chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
Sponsors
Sun Yat-sen University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL) * Tumor size \>7 cm with a portal vein invasion, and the tumor was considered to be unresectable * No previous HCC directed treatment * Eastern Co-operative Group performance status 0-1 * Liver function: Child's A
Exclusion criteria
* Avascular tumor * Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy * underlying serve cardiac or renal diseases * Known or suspected allergy to the investigational agent or any agent given in association with this trial * Diffuse-type HCC * For patients with main portal vein occlusion, no adequate collateral circulation around the occluded portal vein
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| survival rates | 6, 12 months |
Secondary
| Measure | Time frame |
|---|---|
| quality of life | 6, 12 months |
Countries
China
Outcome results
None listed